CAMP displays a tumorigenic effect in ovarian cancer [24], lung cancer [25], breast cancer [26], prostate cancer [27], pancreatic cancer [28], malignant melanoma [29], and skin squamous cell carcinoma [30]. This evidence concerns the gene CAMP and breast carcinoma.